TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Theravance Biopharma; Theravance Biopharma Antibiotics, Inc.
• Treatments: Cephalosporins; Vancomycin

Criteria

Inclusion Criteria:

• major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections

• requires at least 7 days of intravenous antibiotic treatment

Exclusion Criteria:

• more than 24 hours of antibiotic therapy

• moderate or severe liver disease

• severely neutropenic

• baseline QTc > 500 msec, congenital long QT syndrome, uncompensated heart failure, uncorrected abnormal K+ or Mg++ blood levels or severe left ventricular hypertrophy